Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma

study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)

Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)

AntiPD1 ( immunothérapy)

Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)

hypertonic enema solution

expérimental drug placebo of MaaT013